Thiazolidinediones improve β-cell function in type 2 diabetic patients
- 1 March 2007
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 292 (3), E871-E883
- https://doi.org/10.1152/ajpendo.00551.2006
Abstract
Thiazolidinediones (TZDs) improve glycemic control and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). There is growing evidence from in vivo and in vitro studies that TZDs improve pancreatic β-cell function. The aim of this study was to determine whether TZD-induced improvement in glycemic control is associated with improved β-cell function. We studied 11 normal glucose-tolerant and 53 T2DM subjects [age 53 ± 2 yr; BMI 29.4 ± 0.8 kg/m2; fasting plasma glucose (FPG) 10.3 ± 0.4 mM; Hb A1c8.2 ± 0.3%]. Diabetic patients were randomized to receive placebo or TZD for 4 mo. Subjects received 1) 2-h OGTT with determination of plasma glucose, insulin, and C-peptide concentrations and 2) two-step euglycemic insulin (40 and 160 mUm−2min−1) clamp with [3-3H]glucose. T2DM patients were then randomized to receive 4 mo of treatment with pioglitazone (45 mg/day), rosiglitazone (8 mg/day), or placebo. Pioglitazone and rosiglitazone similarly improved FPG, mean plasma glucose during OGTT, Hb A1c, and insulin-mediated total body glucose disposal (Rd) and decreased mean plasma FFA during OGTT (all P < 0.01, ANOVA). The insulin secretion/insulin resistance (disposition) index [ΔISR(AUC)/Δglucose(AUC) ÷ IR] was significantly improved in all TZD-treated groups: +1.8 ± 0.7 (PIO + drug-naïve diabetics), +0.7 ± 0.3 (PIO + sulfonylurea-treated diabetics), and 0.7 ± 0.2 (ROSI + sulfonylurea-withdrawn diabetics) vs. −0.2 ± 0.3 in the two placebo groups ( P < 0.01, all TZDs vs. placebo, ANOVA). Improved insulin secretion correlated positively with increased body weight, fat mass, and Rdand inversely with decreased plasma glucose and FFA during the OGTT. In T2DM patients, TZD treatment leads to improved β-cell function, which correlates strongly with improved glycemic control.Keywords
This publication has 63 references indexed in Scilit:
- The Effect of Pioglitazone on the LiverDiabetes Care, 2006
- Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-γ activity in 3T3-L1 adipocytesBiochemical and Biophysical Research Communications, 2005
- Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretionAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patientsInternational Journal of Obesity, 2004
- Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetesAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in HumansDiabetes Care, 2003
- The Mechanisms of Action of PPARsAnnual Review of Medicine, 2002
- Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.JCI Insight, 1997